Skip to content

Clinical trials

Arthritis, Rheumatoid trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Arthritis, Rheumatoid Country / region: France Clear all

355 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20013
20022
20035
20043
200514
20066
200711
200818
200914
201010
201119
201218
201317
201414
201517
201625
201715
201813
201919
202028
202118
202212
202319
20244
202518
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed218
Terminated40
Unknown status38
Recruiting30
Active, not recruiting19
Not yet recruiting7
Withdrawn3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hoffmann-La Roche32
University Hospital, Montpellier27
Assistance Publique - Hôpitaux de Paris26
Bristol-Myers Squibb18
Centre Hospitalier Universitaire de Saint Etienne11
University Hospital, Clermont-Ferrand11
Pfizer9
Zimmer Biomet8
AstraZeneca7
Centre Hospitalier Universitaire de Nice7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Arthritis, Rheumatoid355
Arthritis, Psoriatic29
Spondylarthritis28
Lupus Erythematosus, Systemic24
Spondylitis, Ankylosing22
Osteoarthritis19
Arthritis16
Crohn Disease14
Sjogren's Syndrome13
Osteonecrosis11

Trials

Showing 76 to 100 of 355. Each trial links to its page on Pharma Observatory.

255 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.